PHAXIAM Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

PHAXIAM Therapeutics şirketinin toplam hissedar öz sermayesi €25.6M ve toplam borcu €13.3M olup, bu da borç-öz sermaye oranını 51.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €51.3M ve €25.7M dir.

Anahtar bilgiler

51.8%

Borç/özkaynak oranı

€13.27m

Borç

Faiz karşılama oranı	n/a
Nakit	€10.47m
Eşitlik	€25.61m
Toplam yükümlülükler	€25.70m
Toplam varlıklar	€51.31m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 2E40 'nin kısa vadeli varlıkları ( €16.2M ) kısa vadeli yükümlülüklerini ( €15.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: 2E40 şirketinin kısa vadeli varlıkları ( €16.2M ) uzun vadeli yükümlülüklerini ( €10.4M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 2E40 'nin net borç/öz sermaye oranı ( 10.9% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: 2E40 şirketinin borç/öz sermaye oranı son 5 yılda 1.4% seviyesinden 51.8% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 2E40 şirketinin mevcut serbest nakit akışına dayanarak yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Tahmini Nakit Akışı: 2E40 tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

PHAXIAM Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

ERYTECH Announces Receipt of Nasdaq Notice

Recent updates

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in U.S

PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

New major risk - Revenue and earnings growth

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

New major risk - Financial position

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

New major risk - Shareholder dilution

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

Insufficient new directors

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

No longer forecast to breakeven

Forecast to breakeven in 2023

Revenue misses expectations

New 90-day low: €6.90

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

New 90-day high: €8.81

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

New 90-day high: €7.70

New 90-day high: €6.33

Revenue misses expectations

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

New 90-day low: €4.30

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

New 90-day low: €4.82

New 90-day low - €6.02

New 90-day low - €6.62

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin